Crystalys Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
12544 High Bluff Dr Ste 310, San Diego, ...Website
www.crystalystx.comRevenue
<$5 MillionIndustry
About Crystalys Therapeutics
Based in San Diego, California, Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. Headquartered in San Diego, California, and co-founded by Catalys Pacific and Novo Holdings, Crystalys brings together a world-class team with deep expertise in gout drug development, dedicated to delivering more effective options for people living with gout. The company's lead candidate, dotinurad, is a next-generation, once daily oral, URAT1 inhibitor in clinical development as a second-line therapy aimed to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has obtained regulatory approval in Japan, China, Philippines and Thailand. With best-in-class potential for both safety and efficacy, dotinurad is supported by clinical data from multiple Asian markets where it is approved. Crystalys is advancing dotinurad in global Phase 3 trials toward regulatory approval and commercial launch.Explore more
SIC Code 28,283NAICS Code 32,325Show moreCrystalys Therapeutics Org Chart
Crystalys Therapeutics Tech Stack
A closer look at the technologies used by Crystalys Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Crystalys Therapeutics
Sign Up For FreeTo access detailed company insights
Based in San Diego, California, Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. Headquartered in San Diego, California, and co-founded by Catalys Pacific and Novo Holdings, Crystalys brings together a world-class team with deep expertise in gout drug development, dedicated to delivering more... Read More
